Do analysts rate NBIX or TAK?

Neurocrine Biosciences currently has a consensus target price of $201.09, indicating a potential upside of 44.16%. Given Neurocrine Biosciences' higher possible upside, research analysts clearly believe Neurocrine Biosciences is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurocrine Biosciences 0 Sell rating(s) 4 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.88 Takeda Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.00

Does the media prefer NBIX or TAK?

In the previous week, Takeda Pharmaceutical had 1 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 10 mentions for Takeda Pharmaceutical and 9 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.72 beat Takeda Pharmaceutical's score of 0.42 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 4 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 1 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor NBIX or ONC?

In the previous week, Neurocrine Biosciences had 7 more articles in the media than BeOne Medicines. MarketBeat recorded 9 mentions for Neurocrine Biosciences and 2 mentions for BeOne Medicines. Neurocrine Biosciences' average media sentiment score of 0.72 beat BeOne Medicines' score of 0.00 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 4 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RPRX or NBIX?

In the previous week, Neurocrine Biosciences had 1 more articles in the media than Royalty Pharma. MarketBeat recorded 9 mentions for Neurocrine Biosciences and 8 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.89 beat Neurocrine Biosciences' score of 0.72 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 4 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NBIX or ZTS?

In the previous week, Zoetis had 2 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 11 mentions for Zoetis and 9 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.72 beat Zoetis' score of -0.28 indicating that Neurocrine Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurocrine Biosciences 4 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Zoetis 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 4 Negative mention(s) 3 Very Negative mention(s) Neutral

Neurocrine Biosciences (NBIX) Competitors

$139.49 -2.76 (-1.94%)

Closing price 04:00 PM Eastern

Extended Trading

$139.00 -0.50 (-0.35%)

As of 07:43 PM Eastern

Compare

NBIX vs. TAK, TEVA, ONC, RPRX, and ZTS

Should you buy Neurocrine Biosciences stock or one of its competitors? Neurocrine Biosciences's main competitors and comparable companies include Takeda Pharmaceutical (TAK), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), Royalty Pharma (RPRX), and Zoetis (ZTS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Neurocrine Biosciences compare to Takeda Pharmaceutical?

Neurocrine Biosciences (NASDAQ:NBIX) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

Neurocrine Biosciences has a net margin of 20.91% compared to Takeda Pharmaceutical's net margin of 3.80%. Neurocrine Biosciences' return on equity of 22.43% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Takeda Pharmaceutical	3.80%	10.95%	5.34%

In the previous week, Takeda Pharmaceutical had 1 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 10 mentions for Takeda Pharmaceutical and 9 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.72 beat Takeda Pharmaceutical's score of 0.42 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	4 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	1 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neurocrine Biosciences has higher earnings, but lower revenue than Takeda Pharmaceutical. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	4.96	$478.60M	$6.82	20.45
Takeda Pharmaceutical	$28.32B	2.13	-$1.01B	$0.34	55.40

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Neurocrine Biosciences has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

Neurocrine Biosciences currently has a consensus target price of $201.09, indicating a potential upside of 44.16%. Given Neurocrine Biosciences' higher possible upside, research analysts clearly believe Neurocrine Biosciences is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88
Takeda Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Neurocrine Biosciences beats Takeda Pharmaceutical on 13 of the 16 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Teva Pharmaceutical Industries?

Neurocrine Biosciences (NASDAQ:NBIX) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, valuation, profitability, analyst recommendations, dividends, earnings and institutional ownership.

Neurocrine Biosciences has a net margin of 20.91% compared to Teva Pharmaceutical Industries' net margin of 4.08%. Teva Pharmaceutical Industries' return on equity of 32.64% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Teva Pharmaceutical Industries	4.08%	32.64%	6.34%

In the previous week, Teva Pharmaceutical Industries had 31 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 40 mentions for Teva Pharmaceutical Industries and 9 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.72 beat Teva Pharmaceutical Industries' score of 0.31 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	4 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	12 Very Positive mention(s)	5 Positive mention(s)	17 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Neurocrine Biosciences has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market.

Neurocrine Biosciences currently has a consensus price target of $201.09, suggesting a potential upside of 44.16%. Teva Pharmaceutical Industries has a consensus price target of $43.73, suggesting a potential upside of 11.83%. Given Neurocrine Biosciences' higher possible upside, equities analysts clearly believe Neurocrine Biosciences is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88
Teva Pharmaceutical Industries	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Teva Pharmaceutical Industries has higher revenue and earnings than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	4.96	$478.60M	$6.82	20.45
Teva Pharmaceutical Industries	$17.26B	2.64	$1.41B	$0.60	65.17

Summary

Neurocrine Biosciences beats Teva Pharmaceutical Industries on 11 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to BeOne Medicines?

Neurocrine Biosciences (NASDAQ:NBIX) and BeOne Medicines (NASDAQ:ONC) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

In the previous week, Neurocrine Biosciences had 7 more articles in the media than BeOne Medicines. MarketBeat recorded 9 mentions for Neurocrine Biosciences and 2 mentions for BeOne Medicines. Neurocrine Biosciences' average media sentiment score of 0.72 beat BeOne Medicines' score of 0.00 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	4 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neurocrine Biosciences currently has a consensus price target of $201.09, suggesting a potential upside of 44.16%. BeOne Medicines has a consensus price target of $402.71, suggesting a potential upside of 10.33%. Given Neurocrine Biosciences' higher probable upside, equities analysts plainly believe Neurocrine Biosciences is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88
BeOne Medicines	0 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.06

Neurocrine Biosciences has higher earnings, but lower revenue than BeOne Medicines. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	4.96	$478.60M	$6.82	20.45
BeOne Medicines	$5.34B	7.50	$286.93M	$5.68	64.26

Neurocrine Biosciences has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, BeOne Medicines has a beta of 0.51, suggesting that its stock price is 49% less volatile than the broader market.

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Neurocrine Biosciences has a net margin of 20.91% compared to BeOne Medicines' net margin of 10.70%. Neurocrine Biosciences' return on equity of 22.43% beat BeOne Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
BeOne Medicines	10.70%	14.23%	7.82%

Summary

Neurocrine Biosciences beats BeOne Medicines on 10 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Royalty Pharma?

Royalty Pharma (NASDAQ:RPRX) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Royalty Pharma has higher earnings, but lower revenue than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.38B	13.94	$770.95M	$1.45	39.76
Neurocrine Biosciences	$2.86B	4.96	$478.60M	$6.82	20.45

Royalty Pharma presently has a consensus target price of $61.29, indicating a potential upside of 6.31%. Neurocrine Biosciences has a consensus target price of $201.09, indicating a potential upside of 44.16%. Given Neurocrine Biosciences' higher probable upside, analysts plainly believe Neurocrine Biosciences is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Neurocrine Biosciences had 1 more articles in the media than Royalty Pharma. MarketBeat recorded 9 mentions for Neurocrine Biosciences and 8 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 0.89 beat Neurocrine Biosciences' score of 0.72 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	4 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Royalty Pharma has a net margin of 32.14% compared to Neurocrine Biosciences' net margin of 20.91%. Royalty Pharma's return on equity of 30.01% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	32.14%	30.01%	14.91%
Neurocrine Biosciences	20.91%	22.43%	15.64%

54.4% of Royalty Pharma shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 18.8% of Royalty Pharma shares are held by insiders. Comparatively, 4.6% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Royalty Pharma has a beta of 0.44, indicating that its share price is 56% less volatile than the broader market. Comparatively, Neurocrine Biosciences has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Summary

Royalty Pharma beats Neurocrine Biosciences on 9 of the 17 factors compared between the two stocks.

How does Neurocrine Biosciences compare to Zoetis?

Neurocrine Biosciences (NASDAQ:NBIX) and Zoetis (NYSE:ZTS) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

In the previous week, Zoetis had 2 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 11 mentions for Zoetis and 9 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.72 beat Zoetis' score of -0.28 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	4 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Zoetis	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	4 Negative mention(s)	3 Very Negative mention(s)	Neutral

Zoetis has a net margin of 27.49% compared to Neurocrine Biosciences' net margin of 20.91%. Zoetis' return on equity of 74.89% beat Neurocrine Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	20.91%	22.43%	15.64%
Zoetis	27.49%	74.89%	18.59%

Zoetis has higher revenue and earnings than Neurocrine Biosciences. Zoetis is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$2.86B	4.96	$478.60M	$6.82	20.45
Zoetis	$9.47B	3.13	$2.67B	$6.07	11.81

Neurocrine Biosciences presently has a consensus price target of $201.09, indicating a potential upside of 44.16%. Zoetis has a consensus price target of $101.08, indicating a potential upside of 41.04%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Neurocrine Biosciences is more favorable than Zoetis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88
Zoetis	2 Sell rating(s)	9 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.32

Neurocrine Biosciences has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market. Comparatively, Zoetis has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

92.6% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 92.8% of Zoetis shares are owned by institutional investors. 4.6% of Neurocrine Biosciences shares are owned by company insiders. Comparatively, 0.2% of Zoetis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Neurocrine Biosciences beats Zoetis on 9 of the 17 factors compared between the two stocks.

Get Neurocrine Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBIX vs. The Competition

Export

Metric	Neurocrine Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.46B	$12.41B	$7.21B	$13.10B
Dividend Yield	N/A	2.63%	2.53%	13.00%
P/E Ratio	20.45	794.80	274.58	25.69
Price / Sales	4.96	833.33	639.38	80.65
Price / Cash	28.38	86.22	76.31	52.02
Price / Book	4.27	10.62	10.44	6.32
Net Income	$478.60M	$2.81B	$3.49B	$359.73M
7 Day Performance	-6.70%	0.73%	0.51%	1.35%
1 Month Performance	-8.57%	-1.67%	-3.38%	-3.68%
1 Year Performance	-4.72%	3.07%	16.04%	5.56%

Neurocrine Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBIX Neurocrine Biosciences	4.7838 of 5 stars	$139.49 -1.9%	$201.09 +44.2%	-3.0%	$14.46B	$2.86B	20.45	2,000
TAK Takeda Pharmaceutical	1.6471 of 5 stars	$18.61 +1.9%	N/A	+26.1%	$58.51B	$4.62T	54.72	47,000
TEVA Teva Pharmaceutical Industries	3.7784 of 5 stars	$38.34 +3.4%	$43.10 +12.4%	+109.6%	$43.22B	$17.26B	63.89	33,950	Trending News Analyst Forecast Insider Trade
ONC BeOne Medicines	2.7405 of 5 stars	$353.83 +2.1%	$402.71 +13.8%	+9.0%	$38.04B	$5.34B	62.29	12,000	Positive News Analyst Upgrade
RPRX Royalty Pharma	3.8941 of 5 stars	$59.05 +0.8%	$61.29 +3.8%	+63.2%	$33.70B	$2.38B	40.72	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBIX) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neurocrine Biosciences (NBIX) Competitors

NBIX vs. TAK, TEVA, ONC, RPRX, and ZTS

How does Neurocrine Biosciences compare to Takeda Pharmaceutical?

Summary

How does Neurocrine Biosciences compare to Teva Pharmaceutical Industries?

Summary

How does Neurocrine Biosciences compare to BeOne Medicines?

Summary

How does Neurocrine Biosciences compare to Royalty Pharma?

Summary

How does Neurocrine Biosciences compare to Zoetis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBIX vs. The Competition

Neurocrine Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neurocrine Biosciences (NBIX) Competitors

NBIX vs. TAK, TEVA, ONC, RPRX, and ZTS

How does Neurocrine Biosciences compare to Takeda Pharmaceutical?

Is NBIX or TAK more profitable?

Does the media prefer NBIX or TAK?

Which has preferable earnings and valuation, NBIX or TAK?

Do insiders and institutionals believe in NBIX or TAK?

Which has more volatility & risk, NBIX or TAK?

Do analysts rate NBIX or TAK?

Summary

How does Neurocrine Biosciences compare to Teva Pharmaceutical Industries?

Is NBIX or TEVA more profitable?

Does the media favor NBIX or TEVA?

Which has more volatility & risk, NBIX or TEVA?

Do analysts prefer NBIX or TEVA?

Do insiders & institutionals hold more shares of NBIX or TEVA?

Which has better valuation & earnings, NBIX or TEVA?

Summary

How does Neurocrine Biosciences compare to BeOne Medicines?

Does the media favor NBIX or ONC?

Do analysts recommend NBIX or ONC?

Which has better valuation and earnings, NBIX or ONC?

Which has more volatility & risk, NBIX or ONC?

Do insiders and institutionals hold more shares of NBIX or ONC?

Is NBIX or ONC more profitable?

Summary

How does Neurocrine Biosciences compare to Royalty Pharma?

Which has stronger valuation & earnings, RPRX or NBIX?

Do analysts prefer RPRX or NBIX?

Does the media refer more to RPRX or NBIX?

Is RPRX or NBIX more profitable?

Do insiders & institutionals have more ownership in RPRX or NBIX?

Which has more volatility & risk, RPRX or NBIX?

Summary

How does Neurocrine Biosciences compare to Zoetis?

Does the media favor NBIX or ZTS?

Is NBIX or ZTS more profitable?

Which has preferable earnings and valuation, NBIX or ZTS?

Do analysts rate NBIX or ZTS?

Which has more risk and volatility, NBIX or ZTS?

Do insiders and institutionals believe in NBIX or ZTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBIX vs. The Competition

Neurocrine Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools